Fradet Y - Search Results

1

Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.

Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Saad F, et al. Among authors: fradet y. Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16. Eur Urol. 2015. PMID: 25985882 Free PMC article.

2

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group.

Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D, Fradet Y, Barkin J, Chin J, Paquin JM, Bullock MJ, Laplante S. Goldenberg SL, et al. Among authors: fradet y. J Urol. 1996 Sep;156(3):873-7. J Urol. 1996. PMID: 8709351 Clinical Trial.

3

Dietary fat and advanced prostate cancer.

Bairati I, Meyer F, Fradet Y, Moore L. Bairati I, et al. Among authors: fradet y. J Urol. 1998 Apr;159(4):1271-5. J Urol. 1998. PMID: 9507851

4

Phenotypic characterization of bladder cancer.

Fradet Y. Fradet Y. Eur Urol. 1998;33 Suppl 4:5-6. doi: 10.1159/000052250. Eur Urol. 1998. PMID: 9615196 Review. No abstract available.

5

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group.

Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P. Debruyne FJ, et al. Among authors: fradet y. Urology. 1998 Jul;52(1):72-81. doi: 10.1016/s0090-4295(98)00129-0. Urology. 1998. PMID: 9671874 Clinical Trial.

6

Downward trend in prostate cancer mortality in Quebec and Canada.

Meyer F, Moore L, Bairati I, Fradet Y. Meyer F, et al. Among authors: fradet y. J Urol. 1999 Apr;161(4):1189-91. J Urol. 1999. PMID: 10081867

7

Dietary fat and prostate cancer progression and survival.

Fradet Y, Meyer F, Bairati I, Shadmani R, Moore L. Fradet Y, et al. Eur Urol. 1999;35(5-6):388-91. doi: 10.1159/000019913. Eur Urol. 1999. PMID: 10325493 Review.

8

Dietary fat and prostate cancer survival.

Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Meyer F, et al. Among authors: fradet y. Cancer Causes Control. 1999 Aug;10(4):245-51. doi: 10.1023/a:1008913307947. Cancer Causes Control. 1999. PMID: 10482482

9

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.

Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y. Meyer F, et al. Among authors: fradet y. J Urol. 1999 Dec;162(6):2024-8. doi: 10.1016/S0022-5347(05)68092-5. J Urol. 1999. PMID: 10569561 Review.

10

Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.

Meyer F, Bairati I, Bédard C, Lacombe L, Têtu B, Fradet Y. Meyer F, et al. Among authors: fradet y. Urology. 2001 Aug;58(2 Suppl 1):71-7. doi: 10.1016/s0090-4295(01)01245-6. Urology. 2001. PMID: 11502453

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters